BERLIN -- Papers reported at the 2010 Heart Failure Congress included the preliminary results from the first-in-man study of gene therapy for heart failure as well as results from a phase III trial of a novel device for hemodynamic management of heart failure -- topics reviewed in this wrap-up InFocus report.
John McMurray, MBChB, MD, of the University of Glasgow, in Scotland, said this year's Heart Failure Congress was notable both for the wide range of countries represented by both faculty and attendees and for a bumper crop of late-breaking trials.
Moreover, McMurray, who just completed his presidency of the Heart Failure Association, told ѻý executive editor Peggy Peck that results of one of those trials -- the CHAMPION study -- are potentially practice-changing findings.